MedTrace Logo

Vascular Markers During OGTT in Diabetics and First-degree Relatives

NCT02244736 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-03-04

No results posted yet for this study

Summary

Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity. The association between damage of endothelial glycocalyx, impaired arterial elastic properties, and CFR in diabetics and first degree relatives has not been explored. The purpose of this study is to explore the association between damage of endothelial glycocalyx, impaired arterial elastic properties, and CFR in diabetics and first-degree relatives before and after during oral glucose tolerance test (OGTT).

Conditions

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Principal Investigators

  • Ignatios Ikonomidis, MD · 2nd Cardiology Department, University of Athens, Greece

  • George Pavlidis, MD · 2nd Cardiology Department, University of Athens, Greece

  • Vaia Lambadiari, MD · 2nd Department of Internal Medicine , University of Athens, Greece

  • Charalambos Koukoulis, MD · 2nd Cardiology Department, University of Athens, Greece

  • Fotini Kousathana, MD · 2nd Department of Internal Medicine, University of Athens, Greece

  • Maria Varoudi, MD · 2nd Cardiology Department, University of Athens, Greece

  • Vlasios Tritakis, MD · 2nd Cardiology Department, University of Athens, Greece

  • Helen Triantafyllidi, MD · 2nd Cardiology Department, University of Athens, Greece

  • George Dimitriadis, MD · 2nd Department of Internal Medicine, University of Athens, Greece

  • John Lekakis, MD · 2nd Cardiology Department, University of Athens, Greece

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-12-31
Completion
2015-03-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02244736 on ClinicalTrials.gov